IGHE and airway hyperresponsiveness: In this experiment, RosA significantly inhibited the increase in inflammatory cells and Th2 cytokines in bronchoalveolar lavage fluid (BALF), decreased total IgE and Ova-specific IgE concentrations, and significantly improved airway hyperresponsiveness (AHR).